141 filings
Page 6 of 8
DEF 14A
sfg8mm 4kqe08cixv
5 May 20
Definitive proxy
5:04pm
8-K
t0p gnc6ea
23 Mar 20
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
5:19pm
10-K
njetm743
6 Mar 20
Annual report
7:07am
S-8
4kqv9imqjv rz2c
6 Mar 20
Registration of securities for employees
12:00am
8-K
q7ggvyyzjwe
17 Dec 19
Other Events
4:05pm
8-K
9hfvalb1kj7 fv
3 Dec 19
Departure of Directors or Certain Officers
4:56pm
8-K
obl dncq3
13 Nov 19
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
7:13am
8-K
kl6d4d6pe 1u
15 Oct 19
Departure of Directors or Certain Officers
6:52am
8-K
8ey vr9m2s52
20 Sep 19
Departure of Directors or Certain Officers
6:02am
8-K
ns7fdo4ckrz1cs8i
10 Sep 19
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
8:45am
8-K
u5ol und5
13 Aug 19
Results of Operations and Financial Condition
7:05am
10-Q
54xo3hpcgs
19 Jun 19
Quarterly report
4:06pm
8-K
6sdy3rmeaiaevgpjl
24 May 19
Condensed Consolidated Financial Statements
4:47pm
8-K
dul2kc vqhnj
15 May 19
Milestone Pharmaceuticals Announces Closing of Initial Public Offering
5:26pm
S-8
yleeav wj0
9 May 19
Registration of securities for employees
5:24pm
424B4
d6s p80il6hd1nradr
9 May 19
Prospectus supplement with pricing info
4:54pm
EFFECT
3bbodx40lkuqr r9
9 May 19
Notice of effectiveness
12:15am
S-1MEF
ncb70
8 May 19
Registration of additional securities for an S-1
9:07pm